Adding dual-PI3Kδ/γ inhibitor Duvelisib during CAR T cell manufacture yields cells with an enhanced number of memory subsets, normalized CD4/CD8 ratios, increased mitochondrial mass, and epigenetic modifications correlating with enhanced anti-tumor efficacy (239). This evidence concerns the gene CD8A and neoplasm.